Investigators of new drugs must continue to send safety reports of serious and unexpected adverse events to their institutional review boards during the public health emergency of the novel ...

Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome. Whether the addition of ticagrelor to aspirin, as compared with aspirin alone, ...

Length of stay averaged 6.4 days and was longer for patients who had major adverse events compared with those who didn’t ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

Hepatic steatosis is associated with greater noncalcified plaque burden (NCPB) and an increased risk for a MACE.

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as a contemporary drug-eluting stent (DES) with regard to target lesion and ...

The number of adverse events reported with the Evoque transcatheter tricuspid valve replacement (TTVR) system (Edwards Lifesciences) during the first year of commercial use should put operators on ...

In March 2026, the US Department of Justice (DOJ) announced criminal charges against medical device company ExThera Medical Corporation and its ...

Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ongoing studies are needed.

Dr. Pepin concluded her presentation discussing a secondary analysis of the VISION trial assessing the impact of external ...